<DOC>
	<DOCNO>NCT02514967</DOCNO>
	<brief_summary>The purpose study evaluate clinical efficacy blisibimod measure composite responder index subject , despite corticosteroid use , continue seropositive , clinically-active Systemic Lupus Erythematosus ( SLE ) define SELENA-SLEDAI score ≥10 , positive anti-double strand DNA low complement ( C3 C4 ) .</brief_summary>
	<brief_title>CHABLIS7.5 : A Study Efficacy Safety Subcutaneous Blisibimod Subjects With Systemic Lupus Erythematosus With Without Nephritis</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<criteria>Fulfill least 4 diagnostic criterion SLE define American College Rheumatology Active SLE disease define SELENASLEDAI score ≥10 despite ongoing stable corticosteroid therapy Positive antidouble strand DNA ( antidsDNA ) low complement Subjects stable nephritis may enrol 18 year age old Severe active central nervous system lupus Malignancy within past 5 year Known positive HIV and/or positive screen visit hepatitis B , hepatitis C Comorbidities would interfere evaluation study drug effect Active infection require hospitalization treatment parenteral antibiotic within past 60 day history repeat herpetic viral infection History active tuberculosis history tuberculosis infection Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>Lupus Erythematosus , Systemic</keyword>
	<keyword>Autoimmune Diseases</keyword>
	<keyword>A-623</keyword>
	<keyword>Blisibimod</keyword>
	<keyword>Nephritis</keyword>
</DOC>